Research & Development

Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology in-licensed from ExcellGene alongside Syngene’s clone selection and development processes.

The new platform is intended to accelerate ‘enhanced protein production, enabling quicker preclinical and clinical development as well as product launches, thereby reducing time to market’, according to the press release.

The platform should save up to ten weeks compared to traditional cell line development methods, increase predictability and protein yields, as well as supporting mAbs, biosimilars, bispecifics, ADCs and other recombinant proteins.

Alex Del Priore, senior vice president, Manufacturing Services, Syngene International, stated:  “Syngene sees biologics as a key driver of future growth and we are committed to investing in cutting-edge technology to achieve reliability, precision and speed for clients. By combining Syngene’s skills and experience with ExcellGene’s best-in-class cell line development technology, we can expedite getting molecules to market for the people and patients who need them.”

Sridevi Khambhampaty, vice president, Biopharmaceutical Development, Syngene International, commented: “By combining the cell line and transposon-based platform from ExcellGene with our proprietary processes, we are pushing the boundaries in cell line development. This innovative approach will not only accelerate development timelines but also enhance the overall reliability and efficiency of the process, delivering substantial benefits to our clients.”